Abstract
Introduction
This retrospectively cohort study was performed at two hospitals located in Zhejiang Province, 110
China initiated by the Zhejiang Disease Control and Prevention Center (CDC) who has set up 111 routine drug resistance monitoring for TB since 1999(11). Patients aged above 18 who were 112 diagnosed with active MDR-TB were recruited consecutively during March 2012 through 113
December 2015 to obtain full follow-up information. Positive culture for Mycobacterial 114 tuberculosis and resistance to isoniazid and rifampicin proven by drug-susceptibility testing were 115 required at enrolment. Furthermore, the participants were included when their treatment therapies 116 were adapted to WHO recommendations (2016 version) . Patients were excluded when met any of 117 the following criteria: (1) positive for HIV test; (2) history of seizure disorder, mental depression, 118 or severe anxiety; (3) decline to participate in this study. 119
The following information were collected: sociodemographic characteristics, indicators of severity 120 (symptoms and radiologic findings), previous treatment, drug-resistant profiles, and background 121 treatment regimen. Culture and sputum conversion and chest X-rays were performed periodically 122 for treatment outcomes evaluation. Moreover, adverse drug reactions were monitored and 123 promptly managed during the entire treatment course. 124
Approval for collection of data was provided by the ethics committees of Zhejiang CDC. All 125 patients provided written informed consent. 126
127
Definitions 128 MDR-TB was defined as tuberculosis caused by a strain as M. tuberculosis that was resistant to at 129 least isoniazid and rifampicin. XDR-TB was MDR-TB that was also resistant to the 130 fluoroquinolones and any of second-line injectable drugs (capreomycin, kanamycin and amikacin).
Pre-XDR-TB was MDR-TB that was resistant to either a fluoroquinolone or a second-line 132 injectable drug, but not both. In the present study, we use the term simple MDR-TB to refer to 133 those with resistance to just isoniazid and rifampicin and complicated MDR-TB to refer to those 134 with additional resistance beyond isoniazid and rifampicin including pre-XDR-TB and XDR-TB. 135
Standard treatment outcome definitions were applied according to the definitions and reporting 136 framework for TB from WHO in 2013(12) . Cured was defined as treatment completed without 137 evidence of failure and three or more consecutive cultures were negative after the intensive phase. 138
If bacteriological results were lacking (i.e. fewer than three cultures performed), the case was 139 defined as treatment completed. Treatment failure was defined as treatment terminated or need for 140 permanent regimen change of at least two anti-TB drugs because of lack of conversion by the end 141 of the intensive phase, or bacteriological reversion in the continuation phase after conversion to 142 negative, or adverse drug reaction. Default was defined as interruption of treatment for at least 2 143 months not meeting the criteria for failure. This study used the following brief outcomes: 144 favorable outcome was defined as cured and treatment completion; unfavorable outcome was 145 defined as any failure, default or death while on treatment. 146
When assessing the adverse drug reaction, we distinguished two types of side-effects: major 147 side-effects and minor side-effects (13) . The formed referred to any adverse reactions that resulted 148 in temporary or permanent discontinuation of anti-TB drugs, while the later referred to those that 149 only required dose adjustment and/or addition of concomitant treatment. 150
151
Drug susceptibility testing 152 drug susceptibility testing to two first-line drugs (rifampicin, isoniazid) and two second-line drugs 154 (ofloxacin and kanamycin) was performed from the first positive Mycobacterial tuberculosis 155 culture with the use of the proportion method and the result was compared with the standardised 156 strains. The critical drug concentrations of rifampicin, isoniazid, ofloxacin, and kanamycin were 157 40, 0.2, 2, and 30 μg/ml respectively (14) . 158
159

Data management and statistical analysis 160
The clinical data were collected through questionnaires and medical records by trained health 161
workers. For the analysis, patients were divided into two cohorts according to the presence or 162 absence of cycloserine in the background regimen (Cycloserine cohort versus Non-cycloserine 163 cohort). Continuous variables were calculated as mean with standard deviation (SD) and median 164 with interquartile range and were further compared by Mann-Whitney U test. Categorical data 165 were presented as numbers (percentage) and were compared with the use of χ^2 test. 166
The primary outcome was the proportion of favorable treatment in each treatment cohort. 167
Secondary outcome included the efficacy of cycloserine measured by the proportion of conversion 168 within the intensive phase and safety and tolerability of cycloserine measured by the frequency of 169 major and minor reactions. 170
For the primary outcome, all patients' treatment outcomes were identified according to the 171 definitions described above by two clinicians blinded for the background regimen. And the 172 proportion of each treatment outcome for two cohort were calculated. Considering the potential 173 confounders, we further investigated the effect of cycloserine upon the treatment outcome by 174 using a Cox proportional-hazards model. Furthermore, we did the specific subgroup analyses ofpatients with different drug resistance patterns. 176 Two-tailed P value of less than 0.05 was considered statistically significant. All statistical 177 calculations and analyses in this study were performed with the use of SPSS Statistics, version 178
(IBM). 179 180
Results
181
Study population 182
Enrolment of patients began in March 2012 and the follow-up for the last patient was performed 183
by December 2017. A total of 582 patients were assessed for eligibility. 241 patients were 184 excluded because their background regimens were not adapted to WHO recommendations (2016 185 versions) and 11 patients were excluded because the strains from their isolates were identified as 186 nontuberculous mycobacteria. Moreover, three patients with HIV positive and two patients with 187 mental illness in the control group were excluded as well. Consequently, 325 patients confirmed to 188 have an organism resistant to both rifampicin and isoniazid were enrolled, 144 of whom were 189 treated with cycloserine in their background regimen according to WHO guidelines for designated 190 dosages of 500mg or 750mg per day (500mg for 38 patients weight less than 50kg; 750mg for 96 191 patients more than 50kg). All patients' background regimen included one of fluoroquinolones and 192 only two patients in cycloserine group had not been treated with aminoglycosides as the initial 193 treatment. Most of demographic and baseline clinical characteristics were comparable among two 194 treatment cohorts except tuberculosis cavity being more frequent in the cycloserine group. The 195 mean age was 42.9 years and approximately 70% of patients were male. 27.4% (89/325) patients 196
were treated with at least one of fluoroquinolones or aminoglycosides more than 30 days before.
More details could be found in Table 1 . 198
Treatment outcome 200
There was a trend approaching a level of significance in treatment outcome: 100 out of 144 201 (69.4%) cycloserine-treated patients achieved treatment success versus 108 out of 181 (59.7%) 202 non-cycloserine-treated patients (χ^2 test, P=0.089, Table 2 ). The absence to sputum conversion at 203 6 months and severe adverse drug effects resulting in two or more drugs stoppage were the main 204 
Safety assessment 223
Overall, 132 of 144 patients (91%) in the cycloserine group and 161 of 181 patients (89%) in the 224 non-cycloserine group had clinically significant adverse drug reactions. The most frequent adverse 225 events were gastrointestinal effects (nausea and vomiting), arthralgia, liver injury and 226 hypokalaemia in both two treatment groups ( Figure 1 ). Among these 132 patients reporting 227 adverse events in the cycloserine group, 37 (28%) experienced major adverse-effects, whereas 95 228 (72%) patients experienced minor side-effects. Adverse events attributed to cycloserine are shown 229 in Table 4 . Side-effects that were possibly or probably related to cycloserine appeared after a 230 median of 71 days (range 10-331 days) of cycloserine treatment. A total of sixteen patients 231 reported seventeen episodes related to cycloserine, including nine patients discontinued 232 cycloserine temporarily or permanently. We observed eight episodes of headache and cycloserine 233 was permanently withdrawn from the treatment regimen in two patients. Moreover, two cases of 234 seizure, one case of depression, and two cases of anxiety were observed, with these events 235 resulting in cycloserine discontinuation within the first six months of treatment. No suicidal 236 ideation was observed. 237 238
Treatment outcomes stratified by resistance patterns 239
The treatment outcomes were further compared between two groups stratified by resistance 240 patterns (Figure 2 ). Among simple MDR-TB patients, the proportion of treatment success in thecycloserine group was higher than the non-cycloserine group, reaching statistical significance 242 (68/85, 80.0% versus 73/117, 62.4%, P=0.007). For other strata, the treatment success rate in the 243 cycloserine group was almost similar to patients who were not treated with cycloserine. Or rather, 244 among pre-XDR-TB patients, the proportion achieving favorable outcome was 56.3% (27/48) in 245 those receiving cycloserine versus 56.9% (29/51) in those treated without cycloserine (P=0.951); 246 and among XDR-TB patients, the proportion of favorable outcome was 45.5% (5/11) and 46.2% 247 (6/13), respectively (P=0.973). We also calculated the sputum conversion rate at six months and 248 observed no significant difference between two groups regardless of the resistance patterns (data 249 not shown). Moreover, a downward trend in favorable treatment outcome rate was observed with 250 the increase in the extent of drug resistance in both groups. 251
252
Risk factors to unfavorable treatment outcomes 253
The associations between unfavorable treatment outcomes and each baseline variables were firstly 254 assessed with univariate Cox regression model. Those variables with P value < 0.1 would be 255 included into multivariate Cox regression model (Table 3) . Using a Cox regression analysis, we 256 found that a significant risk of unfavorable treatment outcomes related to age older than 60 years 257 The research on tuberculosis treatment has witnessed a clear shift from drug-sensitive tuberculosis 264 to drug-resistant tuberculosis, as more than half of patients with drug-resistant tuberculosis 265 experience treatment failure owing to the weaknesses and intolerability of current treatment 266 regimen for drug-resistant tuberculosis. To improve the treatment outcome, intensified research 267 and innovation, the third pillar of WHO's Post-2015 Global Tuberculosis Strategy, has been 268 emphasized(15). Safer, easier and shorter treatment regimens is a critical target that clinicians are 269 moving forward to. The arrival of novel drugs like delamanid and bedaquiline has offered fresh 270 opportunities(16)(17) but up to now, there are not enough new drugs to establish an entirely new 271 regimen, so that the effective use of existing tools is urgently needed to combat tuberculosis. 272
In this study, we focus on cycloserine, an agent that would be added into the initial treatment 273 regimen in priority for MDR-TB according to WHO recommendation, because the evaluation of 274 this drug is greatly hampered by the lack of randomized controlled trials or cohort studies with a 275 reliable outcome measure. To our knowledge, this is the first controlled study to seek to define or 276 optimise the role of cycloserine in drug-resistant tuberculosis treatment. Our data reported an 277 overall treatment success rate of 69.4% within 24 months in the patients treated with cycloserine. 278
Previous studies suggested that the successful outcome rate ranged from 67.5% to 279 77.0%(18)(9)(19), almost in accordance with our results. There are several possible reasons to 280 explain the slight differences. Firstly, the definition of treatment outcome has been updated and 281 further emphasized the tolerability of the regimens which was likely to be underappreciated before. 282
Secondly, some studies combined adjustive therapy like surgical resection that resulted in 283 improved treatment outcomes(9)(20). Moreover, the accelerated development of pre-XDR-TB and 284 Furthermore, compared with the patients in the non-cycloserine group whose regimens mainly 286 included PAS instead of cycloserine, it is suggesting a significant trending towards improved 287 proportion of favorable treatment outcome after the introduction of cycloserine. Based on the 288 current definition we applied, favorable treatment outcome should meet at least three requirements 289 including sputum culture conversion within six months, no sputum reversion, and no severe 290 adverse drug reactions requiring two or more drugs to be discontinued, which indicates that 291 treatment outcome assessments need to integrate efficacy end-points and safety end-points. 292
Efficacy end-points in this study were mainly measured by time to and proportion of sputum 293 culture conversion. Unlikely drug-susceptible tuberculosis, failure to sputum conversion rather 294 than relapse or sputum reversion accounted for a great proportion of treatment failure (21), 295 suggesting that the current regimens for MDR-TB might not show the strong sterilizing activity. 296
As for cycloserine, our study did not provide sufficient evidence that cycloserine could confer a 297 benefit to culture conversion compared with other standardised treatment regimens. A possible 298 explanation for these results may be that treatment of MDR-TB includes multiple drugs and an 299 observational study without strict placebo controls hardly assesses the efficacy of a single agent. 300
Furthermore, a recent study (22) has showed that more than half of patients with the recommended 301 dosage of 10mg/kg of cycloserine prescription had peak serum concentrations lower than the 302 minimum inhibitory concentrations of the strains isolated from the corresponding patients, 303
suggesting the personal need for adjusting dosages depending on the clinical pharmacokinetic and 304
pharmacodynamic assessments(23). 305
Adverse drug reaction remains problematic during the treatment course for MDR-TB patients. By 306 contrast with other anti-TB agents, ADR attributed to cycloserine was relatively uncommon with afrequency of 11.1%. Therefore, cycloserine might be regarded as a safer alternative agent to those 308 with frequent severe side effects that tend to result in drug discontinuation and eventually 309 unfavorable clinical outcomes. Similar results were found in a meta-analysis that estimated the 310 frequencies of any ADR from cycloserine at 9.1% (95%CI: 6.4-11.7)(24). Neuropsychiatric 311 reactions, as expect, were representative of adverse effects of cycloserine since its central active 312 mechanism as a partial NMDA-agonist and high brain-blood-barrier permeability(25). In this 313 study, headache was one of the most common side-effects of cycloserine reported by patients 314 although almost headache resolved quickly with an adjustment in the dose or the temporary 315 discontinuation of cycloserine. Seizure was rare, mainly associated with high dosages (especially 316 with concentrations levels exceeding 40 μg/ml)(26), co-administration of fluoroquinolones, and 317 alcoholism(25), but all led to the withdrawal of cycloserine in this study. Psychiatric disturbances 318 were also described on rare occasions in our study but were more complicated to manage for 319 clinicians. In detail, depression or anxiety might be partly attributable to the inadequate social 320 support and lacking of confidence owing to previous poor treatment outcomes, such as the patient 321 (P89) of depression who had been infected with Mycobacterium Tuberculosis for more than eight 322 years complicated with post-tuberculosis destroyed lung and complained of unbearable arthralgia 323 during the treatment. The major challenge is the lack of reference standard against which to 324 evaluate psychiatric events. However, the current psychiatric reactions to cycloserine is mainly 325 based on case reports (27) and further controlled studies are needed to validate it scientifically. 326
To explore the role of cycloserine for patients with different resistance patterns, we did a subgroup 327 analysis and observed the significant improvement in treatment outcomes related to cycloserine in 328 simple MDR-TB patients, which was hindered greatly in complicated MDR-TB patients. Thefindings from subgroup analyses suggested cycloserine alone are of less benefit without more 330 effectiveness drugs as linezolid for complicated MDR-TB patients (13) , indicating the requirement 331 for reprioritization of cycloserine when managing highly resistant forms of tuberculosis. The 332 treatment of complicated MDR-TB, especially XDR-TB, has been considered as a conundrum 333 facing clinicians. In accordance, this study identified the limited beneficial impact of the 334 standardised five-drug regimen in complicated MDR-TB, calling for new or repurposed agents to 335 effectively eradicate extensive drug-resistant Mycobacterium Tuberculosis. 336
This retrospective study has several limitations. First, the major limitations derive from the 337 observational study design which precluded us from controlling of confounding bias well and 338 looking at some important topics, especially pharmacokinetic and pharmacodynamic assessments 339 of cycloserine. Secondly, some strains isolated from patients were missing and thus we did not 340 perform the drug susceptibility testing to cycloserine. Moreover, as cycloserine had not been 341 approved in China until 2014, its availability and affordability require further evaluation. 342
To summarize, introduction of cycloserine improved the overall favorable outcome of MDR-TB 343 patients. Cycloserine is considered a better-tolerated agent with infrequent adverse side-effects 344 characterized with neuropsychiatric reactions. For simple MDR-TB patients, we believe our 345 results support the use of cycloserine in the setting of correct patient assessment and monitoring. Table 4 Side effects associated with cycloserine or requiring to withdraw cycloserine.
*Daily CS doses refer to the doses in the background regimen. †Interval time from start of therapy to appearance of side effects (days). Abbreviation: CS, cycloserine; mg, milligram.
